Metformina + Sitagliptina Aurovitas

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metformina + Sitagliptina Aurovitas, is a Biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients. The combination improves glycemic control by reducing hepatic glucose production and enhancing incretin‑mediated insulin secretion.

GNH USA supplies Metformina + Sitagliptina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics for prescription medicines.

Metformina + Sitagliptina Aurovitas is used in the management of type 2 diabetes mellitus, targeting hyperglycemia through combined biguanide and DPP‑4 inhibition.

- Type 2 diabetes mellitus (monotherapy): Provides glycemic control when diet and exercise alone are insufficient. - Type 2 diabetes mellitus (combination therapy): Enhances glucose lowering when added to other antidiabetic agents such as insulin or sulfonylureas. - Type 2 diabetes mellitus (adjunct to lifestyle): Supports blood sugar management alongside diet, exercise, and weight‑loss interventions.

The most frequently reported adverse reactions and the less common but serious events associated with Metformina + Sitagliptina Aurovitas are listed below.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain in the abdomen. - Headache: mild tension‑type headache.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

Before prescribing Metformina + Sitagliptina Aurovitas, clinicians should consider the following precautions.

- Renal function assessment: evaluate creatinine clearance to avoid metformin accumulation. - Hepatic impairment: monitor liver enzymes as reduced function may increase risk of lactic acidosis. - Risk of hypoglycemia: adjust dose of concomitant insulin or sulfonylureas to prevent low blood glucose. - Pregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant. - Contraindications: avoid in patients with known hypersensitivity to either component. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Metformina + Sitagliptina Aurovitas may interact with several medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Renal impairment agents (e.g., iodinated contrast media): increase risk of metformin‑associated lactic acidosis. - Insulin or sulfonylureas: may cause severe hypoglycemia when combined. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - ACE inhibitors or ARBs: concurrent use may affect renal function, requiring monitoring. - Thiazide diuretics: can attenuate the glucose‑lowering effect of the combination.